➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Colorcon
McKinsey
Baxter
Merck

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,687,454


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,687,454 protect, and when does it expire?

Patent 9,687,454 protects SUBOXONE and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 9,687,454
Title:Sublingual and buccal film compositions
Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.
Inventor(s): Myers; Garry L. (Kingsport, TN), Hilbert; Samuel D. (Jonesboro, TN), Boone; Bill J. (Johnson City, TN), Bogue; Beuford Arlie (Valparaiso, IN), Sanghvi; Pradeep (Valparaiso, IN), Hariharan; Madhusudan (Munster, IN)
Assignee: Indivior UK Limited (Slough, GB)
Application Number:14/989,669
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,687,454
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 9,687,454

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-001 Aug 30, 2010 AB RX Yes No   Start Trial   Start Trial Y TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION   Start Trial
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-003 Aug 10, 2012 AB RX Yes No   Start Trial   Start Trial Y TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION   Start Trial
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-002 Aug 30, 2010 AB RX Yes No   Start Trial   Start Trial Y TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
Merck
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.